• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SD filed by The Cooper Companies Inc.

    5/30/25 4:20:18 PM ET
    $COO
    Ophthalmic Goods
    Health Care
    Get the next $COO alert in real time by email
    SD 1 formsd-specializeddisclosu.htm SD Document




    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    FORM SD
    Specialized Disclosure Report
    THE COOPER COMPANIES, INC.
    (Exact name of registrant as specified in its charter)

    Delaware
    (State or other jurisdiction of incorporation)
    1-8597
    (Commission File Number)
    94-2657368
    (I.R.S. Employer Identification No.)
    6101 Bollinger Canyon Road, Suite 500
    San Ramon, California 94583
    (Address of principal executive offices) (Zip Code)


    Nicholas S. Khadder (925) 460-3600
    (Name and telephone number, including area code, of the person to contact in connection with this report.)


    Check the appropriate box to indicate the rule pursuant to which this form is being filed, and provide the period to which the information in this form applies:
    ☒    Rule 13p-1 under the Securities Exchange Act (17 CFR 240.13p-1) for the reporting period from January 1 to December 31, 2024.




    SECTION 1.    CONFLICT MINERALS DISCLOSURE

    Item 1.01 and 1.02    Conflict Minerals Disclosure and Report; Exhibit

    A copy of the Conflict Minerals Report for The Cooper Companies, Inc. for the period January 1, 2024 to December 31, 2024 is provided as Exhibit 1.01 hereto and is also publicly available at: investor.coopercos.com/corporate-governance.
    The content of any website referred to in this Form SD, including any exhibit hereto, is included for general information only and is not incorporated by reference into this Form SD.

    SECTION 2.    RESOURCE EXTRACTION ISSUER DISCLOSURE
    Item 2.01    Resource Extraction Issuer Disclosure and Report

    Not applicable.

    SECTION 3.     EXHIBITS
    Item 3.01     Exhibits

    Exhibit No.Document Description
    1.01
    Conflict Minerals Report for The Cooper Companies, Inc. for reporting period ending December 31, 2024





    SIGNATURE

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.






    THE COOPER COMPANIES, INC.



    By:     /s/ Nicholas S. Khadder    
        Nicholas S. Khadder
        General Counsel & Corporate Secretary
            

    Date: May 30, 2025

    Get the next $COO alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $COO

    DatePrice TargetRatingAnalyst
    7/22/2025$92.00Neutral → Outperform
    BNP Paribas Exane
    6/17/2025$94.00Hold → Buy
    Needham
    5/30/2025$76.00Overweight → Neutral
    Analyst
    8/29/2024$115.00 → $120.00Overweight
    Piper Sandler
    7/16/2024$107.00 → $115.00Hold → Buy
    Jefferies
    3/19/2024$125.00Neutral → Buy
    Redburn Atlantic
    3/13/2024$100.00 → $120.00Neutral → Overweight
    JP Morgan
    2/6/2024Sector Weight
    KeyBanc Capital Markets
    More analyst ratings

    $COO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Carbone Barbara

    4 - COOPER COMPANIES, INC. (0000711404) (Issuer)

    5/5/25 4:16:23 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    SEC Form 3 filed by new insider Carbone Barbara

    3 - COOPER COMPANIES, INC. (0000711404) (Issuer)

    5/5/25 4:14:05 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    Director Kozy William A converted options into 2,857 shares, increasing direct ownership by 10% to 31,149 units (SEC Form 4)

    4 - COOPER COMPANIES, INC. (0000711404) (Issuer)

    4/3/25 4:09:38 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    $COO
    SEC Filings

    View All

    SEC Form SD filed by The Cooper Companies Inc.

    SD - COOPER COMPANIES, INC. (0000711404) (Filer)

    5/30/25 4:20:18 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    SEC Form 10-Q filed by The Cooper Companies Inc.

    10-Q - COOPER COMPANIES, INC. (0000711404) (Filer)

    5/30/25 4:19:23 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    SEC Form 8-K filed by The Cooper Companies Inc.

    8-K - COOPER COMPANIES, INC. (0000711404) (Filer)

    5/29/25 4:31:50 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    $COO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    CooperVision Canada Marks Fifth Year of Raising Awareness About Childhood Myopia and Treatment Options

    TORONTO, Aug. 18, 2025 /CNW/ - For the fifth year in a row, CooperVision Canada is investing in educating parents and raising awareness about myopia (aka nearsightedness) in children, emphasizing that it is more than just a blurry vision issue, it is a progressive condition that requires proactive management to help protect long-term eye health and preserve future opportunities for children. MiSight® 1 day contact lenses from CooperVision can help age-appropriate children with myopia reach their full potential. MiSight® 1 day is the first and only FDA approved* soft contact le

    8/18/25 4:16:00 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    CooperCompanies to Participate in the Wells Fargo Healthcare Conference

    SAN RAMON, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading global medical device company, announced today it will participate in the Wells Fargo Healthcare Conference on Wednesday, September 3, 2025. Al White, President and CEO, will represent the Company in a session scheduled at 3:00 PM ET. The webcast will be available to investors and other interested parties by accessing the CooperCompanies' website at http://investor.coopercos.com. About CooperCompaniesCooperCompanies (NASDAQ:COO) is a leading global medical device company focused on helping people experience life's beautiful moments through its two business units, CooperVision and CooperSurgical.

    8/14/25 4:15:00 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    CooperCompanies Announces Release Date for Third Quarter 2025

    SAN RAMON, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading medical device company, announced today it will report third quarter 2025 financial results on Wednesday, August 27, 2025, at 4:15 PM ET. Following the release, the Company will host a conference call at 5:00 PM ET to discuss the results and current corporate developments. The dial-in number for the call is 800-715-9871 and the conference ID is 3665386. A simultaneous audio webcast and subsequent replay can be accessed at http://investor.coopercos.com. About CooperCompaniesCooperCompanies (NASDAQ:COO) is a leading global medical device company focused on helping people experience life's beaut

    7/24/25 4:15:00 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    $COO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cooper upgraded by BNP Paribas Exane with a new price target

    BNP Paribas Exane upgraded Cooper from Neutral to Outperform and set a new price target of $92.00

    7/22/25 7:47:24 AM ET
    $COO
    Ophthalmic Goods
    Health Care

    Cooper upgraded by Needham with a new price target

    Needham upgraded Cooper from Hold to Buy and set a new price target of $94.00

    6/17/25 7:46:56 AM ET
    $COO
    Ophthalmic Goods
    Health Care

    Cooper downgraded by Analyst with a new price target

    Analyst downgraded Cooper from Overweight to Neutral and set a new price target of $76.00

    5/30/25 8:39:00 AM ET
    $COO
    Ophthalmic Goods
    Health Care

    $COO
    Leadership Updates

    Live Leadership Updates

    View All

    CooperCompanies Appoints Barbara Carbone to Board of Directors

    SAN RAMON, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading global medical device company, announced today that its Board of Directors has appointed Barbara Carbone as an independent director, effective May 1, 2025. Ms. Carbone has also been appointed to serve on the Audit Committee when she joins the Board. Ms. Carbone brings nearly four decades of experience across a wide variety of industries. She spent most of her career at KPMG LLP, from 1981-2019, where she served more than twenty-four years as an Audit Partner. She served on the KPMG Partnership Audit Committee for six years, including three years as the Chairperson, and as the National Partner in

    4/30/25 4:15:00 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    Evolus Announces Appointment of Albert G. White III to Board of Directors

    Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced the appointment of Albert G. White III, President and Chief Executive Officer of The Cooper Companies, Inc. to the Evolus Board of Directors, effective July 1. Mr. White will also serve as a member of Evolus' Compensation Committee. "We are pleased to welcome Al White to the Evolus Board," said Vik Malik, Chairman of the Board of Directors. "Al's extensive leadership experience, industry knowledge, and proven track record of building a leading medical technology company will be a valuable resource as Evolus embarks on a path from a single-product aes

    7/1/24 8:00:00 AM ET
    $COO
    $EOLS
    Ophthalmic Goods
    Health Care
    Biotechnology: Pharmaceutical Preparations

    CooperCompanies Appoints Lawrence E. Kurzius to Board of Directors

    SAN RAMON, Calif., Nov. 30, 2023 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO) announced today that its Board of Directors has appointed Lawrence E. Kurzius as an independent director, effective December 1, 2023. Kurzius has also been appointed to serve on the Audit Committee and Organization & Compensation Committee when he joins the Board. "We are thrilled to welcome Lawrence to our Board of Directors," said Al White, President and CEO. "His track record of successfully leading a complex, multinational organization will be extremely valuable to CooperCompanies as we continue to drive global growth at CooperVision and CooperSurgical." Kurzius served as Chief Executive Officer of McCo

    11/30/23 4:15:00 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    $COO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by The Cooper Companies Inc. (Amendment)

    SC 13G/A - COOPER COMPANIES, INC. (0000711404) (Subject)

    2/16/24 4:57:01 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    SEC Form SC 13G filed by The Cooper Companies Inc.

    SC 13G - COOPER COMPANIES, INC. (0000711404) (Subject)

    2/14/24 10:04:33 AM ET
    $COO
    Ophthalmic Goods
    Health Care

    SEC Form SC 13G/A filed by The Cooper Companies Inc. (Amendment)

    SC 13G/A - COOPER COMPANIES, INC. (0000711404) (Subject)

    2/13/24 5:02:29 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    $COO
    Financials

    Live finance-specific insights

    View All

    CooperCompanies Announces Release Date for Third Quarter 2025

    SAN RAMON, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading medical device company, announced today it will report third quarter 2025 financial results on Wednesday, August 27, 2025, at 4:15 PM ET. Following the release, the Company will host a conference call at 5:00 PM ET to discuss the results and current corporate developments. The dial-in number for the call is 800-715-9871 and the conference ID is 3665386. A simultaneous audio webcast and subsequent replay can be accessed at http://investor.coopercos.com. About CooperCompaniesCooperCompanies (NASDAQ:COO) is a leading global medical device company focused on helping people experience life's beaut

    7/24/25 4:15:00 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    CooperCompanies Announces Second Quarter 2025 Results

    SAN RAMON, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading global medical device company, today announced financial results for its fiscal second quarter ended April 30, 2025. Revenue increased 6% year-over-year to $1,002.3 million. CooperVision (CVI) revenue up 5% to $669.6 million, and CooperSurgical (CSI) revenue up 8% to $332.7 million.GAAP diluted earnings per share (EPS) of $0.44, consistent with last year's second quarter.Non-GAAP diluted EPS of $0.96, up $0.11 or 14% from last year's second quarter. See "Reconciliation of Selected GAAP Results to Non-GAAP Results" below. Commenting on the results, Al White, CooperCompanies' President and CEO said,

    5/29/25 4:15:00 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    CooperCompanies Announces Release Date for Second Quarter 2025

     SAN RAMON, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading medical device company, announced today it will report second quarter 2025 financial results on Thursday, May 29, 2025, at 4:15 PM ET. Following the release, the Company will host a conference call at 5:00 PM ET to discuss the results and current corporate developments. The dial-in number for the call is 800-715-9871 and the conference ID is 1515103. A simultaneous audio webcast and subsequent replay can be accessed at http://investor.coopercos.com. About CooperCompaniesCooperCompanies (NASDAQ:COO) is a leading global medical device company focused on helping people experience life's beautiful

    4/29/25 4:15:00 PM ET
    $COO
    Ophthalmic Goods
    Health Care